CEDAX
CEFTIBUTEN DIHYDRATE
Approval overview CEDAX is listed in Drugs@FDA under application 050686 (NDA).
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
Structured Monograph
Clinical summary
Approval overview CEDAX is listed in Drugs@FDA under application 050686 (NDA). Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFTIBUTEN DIHYDRATE Form and strength FOR SUSPENSION;ORAL - EQ 90MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BURKE THERAP Submission history Latest submission status date: 2011-03-11 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.